Drug intelligence / Profile preview

naomaili

Development stage: Unknown
Lead developer: Carephar
Administration: Oral

Overview

Naomaili is a Traditional Chinese Medicine (TCM) formulation approved by the National Medical Products Administration (NMPA) of China in December 2014 for the treatment of ischemic stroke. It is an optimized formula specifically developed for cardio-cerebrovascular diseases and is available as granules. Preclinical studies have demonstrated that Naomaili granules exhibit protective effects against cerebral ischemia and reperfusion injury in animal models, suggesting potential neuroprotective properties relevant to stroke management[1][2][3].

Brand names: Naomaili
Other names: Naomaili granules

Targets

Pyrin inflammasome (Pyrin IF)RHOA (Ras homolog gene family member A)

Beyond the preview

Go deeper on naomaili.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on naomaili.

Explore the full profile